Scandion Oncology hereby informs the market that the information displayed on the public part of Clinicaltrials.gov is not correct: the visible dates for Estimated Primary Completion (May 2021) and Estimated Study Completion (September 2021) are wrongly displayed.
The correct dates, which are in full agreement with all previous information from Scandion Oncology, are as follows: Estimated Primary Completion Date: January 2021 and Estimated Study Completion Date: March 2021.
The correct information has been submitted to ClinicalTrials.gov on January 31, 2020, and will be corrected by ClinicalTrials.gov.
With this Press Release, the market is now informed that the timeline regarding the Estimated Primary Completion and Estimated Study Completion are in accordance with previous information from Scandion oncology.
For further information regarding Scandion Oncology, please contact:
Nils Brünner, CEO
Phone: +45 26 14 47 08
E-mail: nb@scandiononcology.com
This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on February 03 2020.
Scandion Oncology A/S is a biotechnology company addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of drug resistant cancers, which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now initiating clinical phase II trials with its lead compound, SCO-101 in patients with drug resistant cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018.